The T‐cell immunoglobulin‐ and mucin‐domain‐containing molecules (TIMs) comprise a new family of cell surface molecules expressed on T cells. TIM‐3 is expressed on T helper type 1 (Th1) cells and implicated in the pathogenesis of Th1‐driven auto‐ and allo‐immune diseases. TIM‐1 is suggested to act as a co‐stimulatory molecule for all T cells, but with potentially stronger effects on Th2 than Th1 cells and is associated with Th2‐related immune diseases. However, the TIM molecules have not been investigated in the systemic lupus erythematosus (SLE). In this study, we examined the expression of TIM‐1 and TIM‐3 on peripheral blood mononuclear cells from SLE patients using quantitative real‐time RT‐PCR. An increased TIM‐1 expression was detected in SLE patients, which correlates with interleukin‐10 expression. We also found that there was a significant increase in the expression of TIM‐1 in SLE patients with quite active disease (SLE disease activity index > 6), indicating that TIM‐1 expression might be related to active clinical phases. In contrast, TIM‐3 expression remained normal in SLE patients with low statistical power (34.89%). However, the expression of TIM‐3 ligand, galectin‐9 increased in SLE patients indicating an enhanced engagement of TIM‐3 with its ligand in SLE, which may result in a decreased regulatory T‐cell function as shown by the decreased expression of FoxP3 and TGF‐β1 in SLE. These data suggest that TIM‐1 and TIM‐3/TIM‐3L are involved in the pathogenesis of SLE.